Pioneering antigen-agnostic TCR T cell therapies

Get to Know Us

Tcelltech GmbH, a spin-out of the German Cancer Research Center (DKFZ), develops a universal personalised adoptive cell therapy against all cancers (UNIPACT). 

UNIPACT is based on two platform technologies: 

(I) a high-performance gene expression DNA vector platform (nanoSMAR)

(II) an AI bioinformatics platform which identifies reactive T cell receptors (selecTCR).